Research and Markets: Targeted Cancer Drugs The Launch Landscape to 2018

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/324666/targeted_cancer_dr) has announced the addition of the "Targeted Cancer Drugs The Launch Landscape to 2018" report to their offering.

As the cancer therapy market evolves, interest is growing in novel approaches which may supersede the current portfolio. In the short term, the market will be dominated by established therapeutic approaches, but the question is - What next?

A Sign of Things to Come?

The end of 2011 saw the US approval of two new molecularly-targeted cancer drugs, alongside companion diagnostic tests that identify the patients most likely to benefit from treatment. Pfizer's Xalkori (crizotinib) and Roche's Zelboraf (vemurafenib) were both approved following a priority review, highlighting the importance that the FDA has placed on hastening the passage of these therapies to market. These approvals reflect the trend of treating cancers based on their molecular and genetic characteristics, rather than their location within the body.

Such developments have long been heralded as marking the future of cancer therapies and the benefits to patients, clinicians and health payers is clear -but are these approvals the benchmark for future developments?

With sales of many blockbuster drugs being cannibalised by generic competitors, pharmaceutical and biotechnology companies are populating their pipelines with candidates directed at novel targets, enhancing development and commercialisation potential. The opportunities for small and medium-sized companies is increasing as the dynamic of the market changes.

About This Report:

This new report provides a complete assessment of the targeted cancer therapy landscape. Packed with statistics, competitive rankings, timelines and sector share comparisons, this report examines the current market for targeted cancer drugs, with an overview of both products and players. Looking ahead, the report identifies 79 new candidates that are currently under a minimum of Phase II development for solid tumours and provides a timeline detailing estimated launch dates to 2018. There is a review of the molecular targets on which industry attention is focused, and the companies involved in the development and commercialisation of the products directed against these targets. Finally, each product is considered individually in terms of its mode of action, current developmental status, clinical data, risks associated with development, developer and potential competition within the marketplace.

Questions Answered by the Report:

How many products are profiled treating lung, breast and colorectal cancer? Which developmental pathways are much fancied to provide significant clinical advances and which companies are involved? BMS, Eli Lilly, Roche, and Takeda all have five or more products in latestage expected to launch - what are they, what do they target and when are they expected? What are the prospects for Teva Pharmaceutical Industries' oncology portfolio? Emerging opportunities: with whom are the smaller companies working and how many have yet to secure development/marketing collaborations?

For more information visit http://www.researchandmarkets.com/research/324666/targeted_cancer_dr

Source: Espicom Business Intelligence Ltd

View post:
Research and Markets: Targeted Cancer Drugs The Launch Landscape to 2018